Curing with Sound

Launched in 2024, the European Union Focused Ultrasound Foundation (EUFUSF) is the newest sister organization of the Focused Ultrasound Foundation, established to build and strengthen partnerships that expand the reach and impact of focused ultrasound across Europe.  In this episode of Curing with Sound, we speak with Pascale Broks, the Foundation’s Development Director for Europe, who is spearheading the expansion of this transformative technology across the European Union. With over 25 years of experience in development and relationship management, Pascale brings a global perspective and deep passion for connecting people with purpose, driving innovation, and making focused ultrasound accessible to patients from Finland to Greece. Discussion highlights: European Foundation Launch and Strategy: Discover the mission and vision of the newly established EUFUSF, including its distinctive approach to donor engagement, its patient-centered guiding principle, and its goal of making focused ultrasound widely recognized and accessible across Europe. EU FUSF Website EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email [email protected] if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email [email protected] if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

The blood-brain barrier (BBB), while essential for protecting the brain from toxins, has long been one of the greatest obstacles in treating brain diseases, particularly aggressive cancers like glioblastoma. Most chemotherapy drugs simply cannot reach the brain in effective concentrations, leaving patients with limited treatment options and poor outcomes.  In this episode of Curing with Sound, we speak with Graeme Woodworth, MD, Chair of the Department of Neurosurgery at the University of Maryland School of Medicine, whose work is transforming the landscape of brain tumor treatment through the use of focused ultrasound–mediated BBB opening. Dr. Woodworth discusses the role of microbubbles, his efforts to develop a real-time monitoring and dosing strategy for BBB opening, and the exciting results from his multicenter glioblastoma clinical trial. Discussion highlights: Glioblastoma Clinical Trial: Results published in Lancet Oncology report, for the first time, a possible survival benefit among newly diagnosed glioblastoma (GBM) patients treated with focused ultrasound + temozolomide (or TMZ, a chemotherapy drug). Researchers used focused ultrasound to noninvasively open the BBB in GBM patients before administering TMZ. When compared with a matched control group, a 40% increase in overall survival was observed. Published Findings for Measuring and Predicting BBB Opening: Researchers established a real-time, ultrasound-based “dose” measurement—using acoustic emissions from microbubble oscillations—to accurately predict when focused ultrasound will open the blood-brain barrier in glioblastoma patients. They discovered a non-linear dose–response range where blood-brain barrier opening is maximized, enabling safer, more precise, and more effective treatment monitoring. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email [email protected] if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email [email protected] if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

Adenomyosis is a condition in which the uterine lining grows into the muscular wall of the uterus, often causing heavy menstrual bleeding, severe cramping, and chronic pelvic pain. It is estimated to affect 25–60% of women worldwide. Despite its prevalence, treatment options in North America remain extremely limited. Many patients are forced to choose between long-term opioid pain management or a hysterectomy, options that can significantly impact quality of life. In this episode of Curing with Sound, we speak with Dr. Vanda Corbett, a healthcare practitioner who endured decades of debilitating adenomyosis-related pain before discovering focused ultrasound. She first learned about this noninvasive treatment after listening to an episode of the Not Your Mother’s Menopause podcast featuring Suzanne LeBlang, MD, the Foundation’s Director of Clinical Relationships.  Determined to find an alternative to surgery or opioids, Dr. Corbett made the life-changing decision to travel from Dubai to Chongqing Haifu Hospital in China for a focused ultrasound procedure. Her transformative experience has motivated her to share her story, so more women can learn about this revolutionary noninvasive treatment option. Discussion highlights: Medical Travel Experience: Follow Dr. Corbett's journey from Dubai to Chongqing, including the preparation process, travel logistics, and the patient-centered care she received at a specialized focused ultrasound hospital. Immediate Treatment Results and Advocacy Mission: Discover how Dr. Corbett experienced complete pain relief within hours of her procedure, shifting from decades of debilitating symptoms to a return to normal daily life. Learn about her mission to raise awareness of adenomyosis and the potential of focused ultrasound through storytelling and social media. All patient stories featured on the Curing with Sound podcast are personal accounts of an individual’s experience with focused ultrasound treatment. Please be aware that each patient’s situation is unique, and outcomes may vary. The information provided in this story should not be considered as medical advice or a guarantee of specific results. It is important to consult with a qualified healthcare provider to discuss your condition and determine the best treatment options for you. The Focused Ultrasound Foundation does not endorse any specific treatment or medical procedure and encourages all patients to seek professional medical guidance tailored to their individual needs. Watch Dr. Corbett's documentary videos tracking her journey with Adenomyosis and her focused ultrasound treatment. Listen to Dr. Corbett's podcast interview on Dr. Lovely’s Not Your Mother’s Menopause podcast, where she discusses treating Adenomyosis with focused ultrasound. Listen to Dr. Susie LeBlang's podcast interview on Dr. Lovely’s Not Your Mother’s Menopause podcast, where she discusses treating uterine fibroids with focused ultrasound. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email [email protected] if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email [email protected] if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/  

In this episode of Curing with Sound, we explore how focused ultrasound is revolutionizing the field of veterinary medicine. Joanne Tuohy, DVM, PhD, Associate Professor of Surgical Oncology at Virginia Tech’s Animal Cancer Care and Research Center, investigates how histotripsy—a non-thermal focused ultrasound technology—could improve cancer outcomes for veterinary patients while advancing treatments that may benefit both animals and humans. She discusses her clinical trial on osteosarcoma, an aggressive bone cancer that affects dogs and humans in remarkably similar ways.  We also talk with Tasha Hoover, whose two Dobermans participated in Dr. Tuohy’s groundbreaking clinical trials. Both dogs were diagnosed with osteosarcoma at different stages of the research, allowing Tasha to witness firsthand how early trial results shaped the development of treatment protocols. Her story demonstrates the hope that innovative treatments can offer to pet owners and humans facing devastating diagnoses. Discussion highlights: Noninvasive Oncology Innovation: Unlike traditional ablation technologies that use heat, histotripsy employs mechanical stress and pressure to destroy cancer cells, offering a potentially less invasive alternative to amputation while stimulating the immune system to fight remaining cancer cells. One Health Initiative: Dr. Tuohy's histotripsy research for veterinary osteosarcoma could have translational applications for human bone cancer patients, demonstrating how animals and humans can benefit from shared treatment advances under the One Health approach. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email [email protected] if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email [email protected] if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

In this episode of Curing with Sound, we explore a groundbreaking approach to one of medicine’s toughest cancers, glioblastoma (GBM), with Michael Canney, PhD, Chief Scientific Officer at Carthera. GBM is the most aggressive form of brain cancer, notoriously hard to treat because the blood-brain barrier (BBB) blocks many life-saving drugs from reaching tumor cells. With survival rates of just one to two years, new approaches are urgently needed. Dr. Canney shares how Carthera’s SonoCloud-9, an implantable, therapeutic ultrasound device, temporarily opens the BBB and enhances the delivery of circulating drugs to the brain. He also discusses the SONOBIRD clinical trial, comparing the use of Carthera’s SonoCloud-9 device combined with chemotherapy to standard-of-care therapies in patients with recurrent GBM. Discussion highlights: Phase III SONOBIRD Trial: The largest clinical trial in Carthera's history, enrolling 560 patients across the United States and Europe. The trial’s goal is to demonstrate a survival advantage for patients with recurrent GBM when BBB opening is combined with the delivery of carboplatin chemotherapy, as compared with standard of care. Revolutionizing Drug Delivery: How SonoCloud-9 opens the BBB to increase carboplatin concentrations five- to seven-fold, potentially unlocking the full potential of existing cancer drugs that previously couldn’t reach brain tumors. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email [email protected] if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email [email protected] if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/